Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
Aurinia Pharmaceuticals (NASDAQ: AUPH) has appointed Craig Johnson to its Board of Directors to support its next phase of growth. Johnson brings over 30 years of experience in senior financial management and governance roles in the biotechnology industry. He has previously served as director at multiple biotech companies including Ardea Biosciences, Adamis Pharmaceuticals, and Mirati Therapeutics, and currently serves as director at Heron Therapeutics. The company also announced the retirement of Dr. Robert T. Foster from the Board.
Aurinia Pharmaceuticals (NASDAQ: AUPH) ha nominato Craig Johnson nel proprio Consiglio di Amministrazione per supportare la sua prossima fase di crescita. Johnson porta con sé oltre 30 anni di esperienza in ruoli di gestione finanziaria senior e governance nell'industria biotecnologica. Ha precedentemente ricoperto la carica di direttore in diverse aziende biotecnologiche tra cui Ardea Biosciences, Adamis Pharmaceuticals e Mirati Therapeutics, e attualmente è direttore di Heron Therapeutics. Inoltre, l'azienda ha annunciato il ritiro del Dr. Robert T. Foster dal Consiglio.
Aurinia Pharmaceuticals (NASDAQ: AUPH) ha nombrado a Craig Johnson en su Junta Directiva para apoyar su próxima fase de crecimiento. Johnson aporta más de 30 años de experiencia en gestión financiera superior y roles de gobernanza en la industria biotecnológica. Anteriormente, ha servido como director en múltiples empresas biofarmacéuticas, incluyendo Ardea Biosciences, Adamis Pharmaceuticals y Mirati Therapeutics, y actualmente se desempeña como director en Heron Therapeutics. La empresa también anunció la jubilación del Dr. Robert T. Foster de la Junta.
아우리니아 제약 (NASDAQ: AUPH)는 크레이그 존슨을 이사회의 이사로 임명하여 다음 성장 단계 지원을 위해 역할을 할 예정이다. 존슨은 생명공학 산업에서 30년 이상의 고위 재무 관리 및 거버넌스 역할을 수행한 경험이 있다. 그는 Ardea Biosciences, Adamis Pharmaceuticals 및 Mirati Therapeutics를 포함한 여러 생명공학 회사의 이사를 역임하였으며, 현재는 Heron Therapeutics의 이사로 재직 중이다. 또한, 이 회사는 드. 로버트 T. 포스터의 이사회 은퇴를 발표했다.
Aurinia Pharmaceuticals (NASDAQ: AUPH) a nommé Craig Johnson au sein de son Conseil d'Administration pour soutenir sa prochaine phase de croissance. Johnson apporte plus de 30 ans d'expérience dans des rôles de gestion financière senior et de gouvernance dans l'industrie biopharmaceutique. Il a précédemment été directeur dans plusieurs entreprises biopharmaceutiques, y compris Ardea Biosciences, Adamis Pharmaceuticals et Mirati Therapeutics, et il est actuellement directeur chez Heron Therapeutics. La société a également annoncé la retraite du Dr Robert T. Foster du Conseil.
Aurinia Pharmaceuticals (NASDAQ: AUPH) hat Craig Johnson in seinen Vorstand berufen, um die nächste Wachstumsphase zu unterstützen. Johnson bringt über 30 Jahre Erfahrung in leitenden finanziellen Management- und Governance-Rollen in der Biotechnologiebranche mit. Zuvor war er Direktor bei mehreren Biotech-Unternehmen, darunter Ardea Biosciences, Adamis Pharmaceuticals und Mirati Therapeutics, und ist derzeit Direktor bei Heron Therapeutics. Das Unternehmen gab auch die Pensionierung von Dr. Robert T. Foster aus dem Vorstand bekannt.
- Addition of experienced biotech industry veteran with over 30 years of financial management expertise to the Board
- Strategic board restructuring aimed at maximizing shareholder value
- None.
The Company also announced that Dr. Robert T. Foster has retired from the Board.
“As part of our ongoing efforts to ensure that the Board includes the most qualified professionals to help guide the Company to maximize shareholder value, we are pleased to welcome Craig to the Board,” stated Kevin Tang, Chair of the Board. “The Board would also like to thank Robert for his many contributions to the Company.”
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107383259/en/
Media & Investor Inquiries:
Andrea Christopher
Corporate Communications & Investor Relations
Aurinia Pharmaceuticals Inc.
achristopher@auriniapharma.com
General Investor Inquiries:
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
FAQ
Who is the new Board member appointed to Aurinia Pharmaceuticals (AUPH)?
Which board positions has Craig Johnson previously held before joining Aurinia (AUPH)?
Who retired from Aurinia Pharmaceuticals' (AUPH) Board of Directors?
